Terms: = Skin cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Staging
28 results:
1. Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma.
Liu D; Yang F; Zhang T; Mao R
J Transl Med; 2023 Jan; 21(1):57. PubMed ID: 36717900
[TBL] [Abstract] [Full Text] [Related]
2. Metastatic malignant melanoma of the breast: report of a case and review of the literature.
Mastoraki A; Gkiala A; Theodoroleas G; Mouchtouri E; Strimpakos A; Papagiannopoulou D; Schizas D
Folia Med (Plovdiv); 2022 Apr; 64(2):354-358. PubMed ID: 35851793
[TBL] [Abstract] [Full Text] [Related]
3. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Basset-Seguin N; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Forsea AM; Grob JJ; Hoeller C; Kaufmann R; Kelleners-Smeets N; Lallas A; Lebbé C; Lytvynenko B; Malvehy J; Moreno-Ramirez D; Nathan P; Pellacani G; Saiag P; Stratigos AJ; Van Akkooi ACJ; Vieira R; Zalaudek I; Lorigan P;
Eur J Cancer; 2022 Jul; 170():256-284. PubMed ID: 35623961
[TBL] [Abstract] [Full Text] [Related]
4. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
Ascierto PA; Warner AB; Blank C; Caracò C; Demaria S; Gershenwald JE; Khushalani NI; Long GV; Luke JJ; Mehnert JM; Robert C; Rutkowski P; Tawbi HA; Osman I; Puzanov I
J Transl Med; 2022 May; 20(1):200. PubMed ID: 35538491
[TBL] [Abstract] [Full Text] [Related]
5. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
[No Abstract] [Full Text] [Related]
6. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract] [Full Text] [Related]
7. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
Ascierto PA; Atkins MB; Eggermont AM; Gershenwald JE; Grob JJ; Hamid O; Sondak VK; Sosman JA; Tawbi HA; Weber JS; Caracò C; Osman I; Puzanov I
J Transl Med; 2021 Apr; 19(1):142. PubMed ID: 33827575
[TBL] [Abstract] [Full Text] [Related]
8. Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data.
Zhang X; Liang Y
Biomed Res Int; 2021; 2021():8197936. PubMed ID: 33506034
[TBL] [Abstract] [Full Text] [Related]
9. Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndrome.
Calvani J; de Masson A; de Margerie-Mellon C; de Kerviler É; Ram-Wolff C; Gruber A; Meignin V; Brice P; Sadoux A; Mourah S; Bagot M; Battistella M
Br J Dermatol; 2021 Aug; 185(2):419-427. PubMed ID: 33400272
[TBL] [Abstract] [Full Text] [Related]
10. The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
Ascierto PA; Agarwala SS; Eggermont A; Gershenwald JE; Grob JJ; Hamid O; Michielin O; Postow M; Puzanov I; Zarour HM; Caracò C; Testori A
J Transl Med; 2020 Apr; 18(1):171. PubMed ID: 32299446
[TBL] [Abstract] [Full Text] [Related]
11. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Garbe C; Amaral T; Peris K; Hauschild A; Arenberger P; Bastholt L; Bataille V; Del Marmol V; Dréno B; Fargnoli MC; Grob JJ; Höller C; Kaufmann R; Lallas A; Lebbé C; Malvehy J; Middleton M; Moreno-Ramirez D; Pellacani G; Saiag P; Stratigos AJ; Vieira R; Zalaudek I; Eggermont AMM;
Eur J Cancer; 2020 Feb; 126():159-177. PubMed ID: 31866016
[TBL] [Abstract] [Full Text] [Related]
12. Rituximab as a therapeutic option for patients with advanced melanoma.
Winkler JK; Schiller M; Bender C; Enk AH; Hassel JC
Cancer Immunol Immunother; 2018 Jun; 67(6):917-924. PubMed ID: 29516155
[TBL] [Abstract] [Full Text] [Related]
13. Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.
Sidhu P; Menzies AM; Long G; Carlino M; Lorens S; Kapoor R
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):759-766. PubMed ID: 29024572
[TBL] [Abstract] [Full Text] [Related]
14. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.
Garbe C; Peris K; Hauschild A; Saiag P; Middleton M; Bastholt L; Grob JJ; Malvehy J; Newton-Bishop J; Stratigos AJ; Pehamberger H; Eggermont AM; ; ;
Eur J Cancer; 2016 Aug; 63():201-17. PubMed ID: 27367293
[TBL] [Abstract] [Full Text] [Related]
15. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
[TBL] [Abstract] [Full Text] [Related]
16. Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.
Berrocal A; Cabañas L; Espinosa E; Fernández-de-Misa R; Martín-Algarra S; Martínez-Cedres JC; Ríos-Buceta L; Rodríguez-Peralto JL
Adv Ther; 2014 Sep; 31(9):945-60. PubMed ID: 25145549
[TBL] [Abstract] [Full Text] [Related]
17. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing ctla4 monoclonal antibody treatment.
Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
[TBL] [Abstract] [Full Text] [Related]
18. Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients.
Kaufman KL; Mactier S; Armstrong NJ; Mallawaaratchy D; Byrne SN; Haydu LE; Jakrot V; Thompson JF; Mann GJ; Scolyer RA; Christopherson RI
Clin Exp Metastasis; 2014 Apr; 31(4):407-21. PubMed ID: 24435119
[TBL] [Abstract] [Full Text] [Related]
19. Cutaneous melanoma.
Eggermont AM; Spatz A; Robert C
Lancet; 2014 Mar; 383(9919):816-27. PubMed ID: 24054424
[TBL] [Abstract] [Full Text] [Related]
20. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".
Pflugfelder A; Kochs C; Blum A; Capellaro M; Czeschik C; Dettenborn T; Dill D; Dippel E; Eigentler T; Feyer P; Follmann M; Frerich B; Ganten MK; Gärtner J; Gutzmer R; Hassel J; Hauschild A; Hohenberger P; Hübner J; Kaatz M; Kleeberg UR; Kölbl O; Kortmann RD; Krause-Bergmann A; Kurschat P; Leiter U; Link H; Loquai C; Löser C; Mackensen A; Meier F; Mohr P; Möhrle M; Nashan D; Reske S; Rose C; Sander C; Satzger I; Schiller M; Schlemmer HP; Strittmatter G; Sunderkötter C; Swoboda L; Trefzer U; Voltz R; Vordermark D; Weichenthal M; Werner A; Wesselmann S; Weyergraf AJ; Wick W; Garbe C; Schadendorf D; ;
J Dtsch Dermatol Ges; 2013 Aug; 11 Suppl 6():1-116, 1-126. PubMed ID: 24028775
[TBL] [Abstract] [Full Text] [Related]
[Next]
